Curis (CRIS) Gains from Investment Securities (2011 - 2026)

Curis (CRIS) reported Gains from Investment Securities of $12.8 million for Q1 2026, up 9012.14% quarter-over-quarter from $140000.0 in Q4 2020.

Curis (CRIS) Gains from Investment Securities (2011 - 2026) Analysis & Trends

Curis has reported Gains from Investment Securities for 9 years, with the latest figure at $12.8 million in Q1 2026.

For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 9012.14% YoY), and the FY2020 full-year result was $7.2 million, changed N/A from the prior year.
Gains from Investment Securities for Q1 2026 stood at $12.8 million, up from $140000.0 in the prior quarter.
The five-year high for Gains from Investment Securities was $12.8 million in Q1 2026, with the low at $12.8 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Curis	8.58 Mn	-6.42 Mn	-

Download Data